Follow Us:
Olutasidenib Exporter From India

Olutasidenib

Olutasidenib is a targeted anticancer medicine used to treat adults with relapsed or refractory acute myeloid leukaemia (AML) carrying a susceptible IDH1 gene mutation, confirmed by an approved diagnostic test. It works by selectively inhibiting mutated isocitrate dehydrogenase-1 (IDH1), reducing the abnormal production of 2-hydroxyglutarate and helping promote the maturation of leukaemia cells. Olutasidenib is available as oral capsules, with the dose and treatment duration determined by the oncology specialist. Common adverse effects include nausea, fatigue, constipation, diarrhoea, joint pain, fever, and changes in liver function tests. Serious risks include potentially fatal differentiation syndrome and hepatotoxicity, requiring prompt assessment of symptoms such as fever, breathlessness, swelling, or sudden weight gain. Treatment requires specialist oncology supervision, mutation testing, and regular monitoring of blood counts, liver function, and other blood chemistry parameters.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Olutasidenib

Olutasidenib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Olutasidenib

Availability of Olutasidenib

Delivery of Olutasidenib

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Olutasidenib.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Olutasidenib.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Olutasidenib, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Olutasidenib Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Olutasidenib

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Olutasidenib Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Olutasidenib, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Olutasidenib

The export of Olutasidenib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Olutasidenib Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Olutasidenib specifications, certificates of analysis, and other supporting documents required for Olutasidenib export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Olutasidenib export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Olutasidenib regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Olutasidenib documentation, labelling, Olutasidenib manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Olutasidenib Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Olutasidenib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Email Us

info@primeerahealthcare.com

Call Us

+(123) 456 789 00

Follow Us

Primeera Healthcare

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.